| P50 | author | Juliana Maria Reyes-Urueña | Q55979665 |
| | Colin Campbell | Q56524218 |
| | Elia Diez | Q56810228 |
| P2093 | author name string | J Casabona | |
| | V Ortún | |
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 |
| | HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness | Q28474086 |
| | The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study | Q28484308 |
| | The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies | Q28487926 |
| | Sources of HIV infection among men having sex with men and implications for prevention | Q28601386 |
| | Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. | Q30061943 |
| | Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance Data | Q30982952 |
| | New method for estimating HIV incidence and time from infection to diagnosis using HIV surveillance data: results for France | Q33979317 |
| | A mathematical model of comprehensive test-and-treat services and HIV incidence among men who have sex with men in the United States | Q34163174 |
| | Developing guidance for budget impact analysis | Q34309879 |
| | Estimating the size of the MSM populations for 38 European countries by calculating the survey-surveillance discrepancies (SSD) between self-reported new HIV diagnoses from the European MSM internet survey (EMIS) and surveillance-reported HIV diagno | Q35006702 |
| | Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa | Q35120904 |
| | Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada | Q35158119 |
| | Projected Lifetime Healthcare Costs Associated with HIV Infection | Q35526724 |
| | Economic impact of HIV/AIDS: a systematic review in five European countries. | Q35851034 |
| | Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access | Q35875746 |
| | Who Will Use Pre-Exposure Prophylaxis (PrEP) and Why?: Understanding PrEP Awareness and Acceptability amongst Men Who Have Sex with Men in the UK--A Mixed Methods Study | Q35993762 |
| | Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial | Q36426896 |
| | The European preexposure prophylaxis revolution | Q36956187 |
| | Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052. | Q37974037 |
| | What do we know about the cost-effectiveness of HIV preexposure prophylaxis, and is it affordable? | Q38633781 |
| | Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. | Q38963785 |
| | Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study | Q39371497 |
| | Modelling the HIV epidemic among MSM in the United Kingdom: quantifying the contributions to HIV transmission to better inform prevention initiatives | Q39371506 |
| | A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. | Q39456029 |
| | Awareness of Pre-exposure Prophylaxis for HIV, Willingness to Use It and Potential Barriers or Facilitators to Uptake Among Men Who Have Sex with Men in Spain | Q39882521 |
| | The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain | Q40599068 |
| | Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults | Q40599220 |
| | Implementation and Operational Research: A Cost-Effective, Clinically Actionable Strategy for Targeting HIV Preexposure Prophylaxis to High-Risk Men Who Have Sex With Men. | Q40755187 |
| | High HIV incidence among men who have sex with men attending a community-based voluntary counselling and testing service in Barcelona, Spain: results from the ITACA cohort | Q40774373 |
| | A meta-analysis of utility estimates for HIV/AIDS. | Q46061609 |
| | Why some MSM present late for HIV testing: a qualitative analysis | Q58245857 |
| P433 | issue | 6 | |
| P921 | main subject | exposure assessment | Q4008388 |
| | pre-exposure prophylaxis against HIV | Q7239230 |
| P304 | page(s) | 784-792 | |
| P577 | publication date | 2017-12-20 | |
| P1433 | published in | AIDS Care | Q15755470 |
| P1476 | title | Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment | |
| P478 | volume | 30 | |